Serotonergic 5HT

1. A compound of the formula:

R 3 , R 4 are independently H, C 1-3 alkyl, or C 1-3 alkyl substituted optionally with OH or OC 1-3 alkyl;

R 7 , R 8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ 3 -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C 1-3 alkyl, C 1-3 alkyl substituted optionally with OH, OC 1-3 alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF 3 , OC 1-3 alkyl, or C 1-3 alkyl, or substituted on nitrogen with C 1-4 alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF 3 , OC 1-3 alkyl, or C 1-3 alkyl;

R 9 is phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C 1-4 alkyl, halogen, OC 1-4 alkyl;

R 10 is C 1-4 alkyl, or R 10 can be joined to R 9 to form an indoline;

n is 2 to 4

or a pharmaceutically acceptable salt thereof.

2. A method for lowering IOP which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:

R 3 , R 4 are independently H, C 1-3 alkyl, or C 1-3 alkyl substituted optionally with OH or OC 1-3 alkyl;

R 7 , R 8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ 3 -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C 1-3 alkyl, C 1-3 alkyl substituted optionally with OH, OC 1-3 alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF 3 , OC 1-3 alkyl, or C 1-3 alkyl, or substituted on nitrogen with C 1-4 alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF 3 , OC 1-3 alkyl, or C 1-3 alkyl;

R 9 is phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C 1-4 alkyl, halogen, OC 1-4 alkyl;

R 10 is C 1-4 alkyl, or R 10 can be joined to R 9 to form an indoline;

n is 2 to 4

or a pharmaceutically acceptable salt thereof.

3. A method for improving blood flow to the optic nerve head and the retina which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:

R 3 , R 4 are independently H, C 1-3 alkyl, or C 1-3 alkyl substituted optionally with OH or OC 1-3 alkyl;

R 7 , R 8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ 3 -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C 1-3 alkyl, C 1-3 alkyl substituted optionally with OH, OC 1-3 alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF 3 , OC 1-3 alkyl, or C 1-3 alkyl, or substituted on nitrogen with C 1-4 alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF 3 , OC 1-3 alkyl, or C 1-3 alkyl;

R 9 is phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C 1-4 alkyl, halogen, OC 1-4 alkyl;

R 10 is C 1-4 alkyl, or R 10 can be joined to R 9 to form an indoline;

n is 2 to 4

or a pharmaceutically acceptable salt thereof.

4. A method for treating retinal diseases which comprises administering to a person in need thereof, a composition comprising an effective amount of a compound of the formula:

R 3 , R 4 are independently H, C 1-3 alkyl, or C 1-3 alkyl substituted optionally with OH or OC 1-3 alkyl;

R 7 , R 8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ 3 -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C 1-3 alkyl, C 1-3 alkyl substituted optionally with OH, OC 1-3 alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF 3 , OC 1-3 alkyl, or C 1-3 alkyl, or substituted on nitrogen with C 1-4 alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF 3 , OC 1-3 alkyl, or C 1-3 alkyl;

R 9 is phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C 1-4 alkyl, halogen, OC 1-4 alkyl;

R 10 is C 1-4 alkyl, or R 10 can be joined to R 9 to form an indoline;

n is 2 to 4

or a pharmaceutically acceptable salt thereof.

5. A method for treating persons suffering from a sleeping disorder, depression, schizophrenia, anxiety, obsessive compulsive disorders, circadian rhythm disorders, and centrally and peripherally mediated hypertension which comprises, administering a composition comprising a pharmaceutically effective amount of a compound of the formula:

R 3 , R 4 are independently H, C 1-3 alkyl, or C 1-3 alkyl substituted optionally with OH or OC 1-3 alkyl;

R 7 , R 8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ 3 -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C 1-3 alkyl, C 1-3 alkyl substituted optionally with OH, OC 1-3 alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF 3 , OC 1-3 alkyl, or C 1-3 alkyl, or substituted on nitrogen with C 1-4 alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF 3 , OC 1-3 alkyl, or C 1-3 alkyl;

R 9 is phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C 1-4 alkyl, halogen, OC 1-4 alkyl;

R 10 is C 1-4 alkyl, or R 10 can be joined to R 9 to form an indoline;

n is 2 to 4

or a pharmaceutically acceptable salt thereof.

6. A composition comprising a pharmaceutically effective amount of a compound of the formula:

R 3 , R 4 are independently H, C 1-3 alkyl, or C 1-3 alkyl substituted optionally with OH or OC 1-3 alkyl;

R 7 , R 8 are together with the nitrogen atom to which they are attached incorporated into a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, Δ 3 -piperidein, piperazine, morpholine or thiomorpholine which can be unsubstituted or substituted on carbon with one or more substituents optionally selected from C 1-3 alkyl, C 1-3 alkyl substituted optionally with OH, OC 1-3 alkyl, phenyl which can be unsubstituted or substituted optionally with halogen, CF 3 , OC 1-3 alkyl, or C 1-3 alkyl, or substituted on nitrogen with C 1-4 alkoxy or phenyl which can be unsubstituted or substituted optionally with halogen, CF 3 , OC 1-3 alkyl, or C 1-3 alkyl;

R 9 is phenyl or a monocyclic heteroaromatic ring which can be unsubstituted or substituted with C 1-4 alkyl, halogen, OC 1-4 alkyl;

R 10 is C 1-4 alkyl, or R 10 can be joined to R 9 to form an indoline;

n is 2 to 4

or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier.

7. The Compound of claim 1 selected from the group consisting of:

3-[4-(3-Chlorophenyl)piperazin-1-yl]propylsulfonyl-2,3-dihydro-1H-indole;

3-[4-(3-Trifluoromethylphenyl)piperazin-1-yl]propylsulfonyl-2,3-dihydro-1H-indole;

3-[4-(2-Methoxyphenyl)piperazin-1-yl]propylsulfonyl-2,3-dihydro-1H-indole.